Tandem Diabetes Care (TNDM) EBITDA (2013 - 2026)

Tandem Diabetes Care (TNDM) has reported EBITDA for 14 consecutive years, with -$13.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBITDA rose 73.38% year-over-year to -$13.8 million; the trailing twelve-month figure through Jun 2026 stood at -$45.8 million (up 77.03% YoY), and the FY2025 full-year result was -$187.3 million, down 88.91% from the prior year.
• EBITDA grew to -$13.8 million in Q2 2026 per TNDM's latest filing, from -$17.4 million in the prior quarter.
• Across five years, EBITDA topped out at $8.3 million in Q4 2025 and bottomed at -$127.8 million in Q1 2023.
• Historically, EBITDA has averaged -$35.8 million across 5 years, with a median of -$28.4 million in 2024.
• The sharpest annual moves came in 2023 and 2025: EBITDA slumped 733.34% in 2023, then jumped 1527.54% in 2025.
• Over 5 years, EBITDA stood at -$17.8 million in 2022, then slumped by 97.22% to -$35.1 million in 2023, then jumped by 98.34% to -$581000.0 in 2024, then surged by 1527.54% to $8.3 million in 2025, then plunged by 266.29% to -$13.8 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$13.8 million, -$17.4 million, and $8.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.